Company Monitoring Page for AbbVie

latest headlines for company on cafepharma

2 Things About AbbVie That Investors Are Ignoring
Motley Fool
Wed, 05/3/23 - 10:34 pm
Tags:
AbbVie, immunology, aesthetics, Neuroscience
AbbVie, Bristol Myers vied for Prometheus before Merck bought it
Crain's Chicago Business
Mon, 05/1/23 - 10:15 pm
Tags:
Merck, Prometheus Biosciences, M&A, AbbVie, Bristol Myers Squibb
Where Will AbbVie Be in 5 Years?
Motley Fool
Mon, 05/1/23 - 11:09 am
Tags:
AbbVie, Humira, biosimiliars
As Humira biosims take hold, longtime AbbVie CEO Richard Gonzalez talks succession plans
Fierce Pharma
Thu, 04/27/23 - 11:02 pm
Tags:
AbbVie, Pharma CEOs, Richard Gonzalez, Humira, biosimilars
Activist shareholders ask 9 big pharmas to consider whether 'excessive' patenting hurts access
Fierce Pharma
Wed, 04/26/23 - 05:50 pm
Tags:
AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Gilead Sceinces, JNJ, Merck, Pfizer, Regeneron, patents, activists
AAN 2023: AbbVie highlights Qulipta’s edge over oral migraine prophylaxis
Clinical Trials Arena
Wed, 04/26/23 - 10:05 am
Tags:
AbbVie, Qulipta, chronic migraine
Big pharma holds steady on research spending
EP Vantage
Fri, 04/21/23 - 10:03 am
Tags:
R&D, AbbVie, Amgen, AstraZeneca, Bayer, Biogen, Bristol Myers Squibb, Eli Lilly, Gilead Sciences, GSK, JNJ, Merck, Merck KGaA, Moderna Therapeutics, Novartis, Novo Nordisk, Pfizer, Regeneron, Roche, Sanofi, UCB, Vertex Pharmaceuticals
Big pharma’s biggest spenders revealed: 2022 edition
EP Vantage
Fri, 04/21/23 - 10:00 am
Tags:
M&A, R&D, AbbVie, AstraZeneca, Bristol Myers Squibb, Eli Lilly, GSK, JNJ, Merck, Novartis, Pfizer, Roche, Sanofi
FDA expands Qulipta indication to include chronic migraine prevention
Healio
Tue, 04/18/23 - 10:13 pm
Tags:
AbbVie, migraine, FDA, CGRP blockers, Qulipta
In upcoming skin disease clash, doctors see Novartis' Cosentyx as an underdog
Fierce Pharma
Tue, 04/11/23 - 10:04 am
Tags:
Novartis, Cosentyx, AbbVie, Humira, hidradenitis suppurativa, UCB Pharma
AbbVie-sponsored docuseries goes beyond the before and after
Medical Marketing and Media
Mon, 04/10/23 - 04:55 pm
Tags:
AbbVie, pharma marketing, plastic surgery, aesthetics
AbbVie removes two approvals for blood cancer drug Imbruvica
BioPharma Dive
Fri, 04/7/23 - 01:49 pm
Tags:
AbbVie, Imbruvica, cancer
AbbVie knocks down earnings forecast due to IPR&D charge
Fierce Biotech
Thu, 04/6/23 - 11:54 am
Tags:
AbbVie, R&D
Spotlight – following Humira in hidradenitis suppurativa
EP Vantage
Tue, 04/4/23 - 10:10 am
Tags:
AbbVie, Humira, hidradenitis suppurativa, UCB Pharma, Bimzelx, MoonLake Immunotherapeutics
Go or no go? Seagen's Padcev eyes FDA approval
EP Vantage
Mon, 04/3/23 - 09:41 am
Tags:
FDA, AbbVie, Alvotech, Ascendis Pharma, Astellas, AstraZeneca, Biogen, Daiichi Sankyo, Eli Lilly, Ferring Pharmaceuticals, Hugel, Innoviva, Ionis Pharmaceuticals, Lundbeck, Merck, Novo Nordisk, Otsuka, Pfizer, Roche Seagen, Seres Therapeutics, Takeda, UCB, Vertex Pharmaceuticals
This Blockbuster Drug's Latest News Could Be Another Home Run for AbbVie
Motley Fool
Fri, 03/31/23 - 10:16 am
Tags:
Skyrizi, AbbVie, clinical trials, ulcerative colitis
AbbVie sidelines CytomX after seeing midphase oncology ADC data, opens talks on returning lead drug
Fierce Biotech
Tue, 03/28/23 - 10:22 am
Tags:
AbbVie, CytomX Therapeutics, cancer, oncology, antibody-drug conjugate
Top 10 pharma R&D budgets in 2022
Fierce Biotech
Mon, 03/27/23 - 10:21 pm
Tags:
R&D, Roche, JNJ, Merck, Pfizer, Novartis, AstraZeneca, Bristol Myers Squibb, Eli Lilly, Sanofi, AbbVie
AbbVie clinches back-to-back clinical wins in ulcerative colitis, lupus
BioSpace
Fri, 03/24/23 - 11:50 am
Tags:
AbbVie, Skyrizi, ulcerative colitis, lupus, Rinvoq, clinical trials
AbbVie's Skyrizi aces ulcerative colitis study en route to new IBD showdown with J&J, Takeda
Fierce Pharma
Thu, 03/23/23 - 11:39 am
Tags:
AbbVie, Skyrizi, IBD, ulcerative colitis, clinical trials

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.